New York – February 16, 2017 – Cooley advised ObsEva on its $96.8 million initial public offering of 6,450,000 common shares. The underwriters maintain a 30-day option to purchase up to 967,500 additional common shares. The company now trades on the NASDAQ Global Select Market as “OBSV.”
ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.